Travere Therapeutics 2024 Executive Compensation Details
Ticker: TVTX · Form: DEF 14A · Filed: Apr 1, 2025 · CIK: 1438533
| Field | Detail |
|---|---|
| Company | Travere Therapeutics, Inc. (TVTX) |
| Form Type | DEF 14A |
| Filed Date | Apr 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, DEF14A, equity-awards
Related Tickers: TVTX
TL;DR
Travere Therapeutics DEF 14A out: Executive equity awards for 2024 detailed, focusing on PEO and Non-PEO compensation.
AI Summary
Travere Therapeutics, Inc. filed its DEF 14A on April 1, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation, including equity awards granted to its Principal Executive Officer (PEO) and Non-PEO/Neo members. Specific details on the fair value of equity awards granted and outstanding are provided for the fiscal year 2024.
Why It Matters
This filing provides transparency into how Travere Therapeutics compensates its top executives, which can influence investor perception and employee morale.
Risk Assessment
Risk Level: medium — DEF 14A filings, while routine, can reveal information about executive compensation and corporate governance that may impact stock price.
Key Numbers
- 2024 — Fiscal Year End (Reporting period for executive compensation details.)
- 20250401 — Filing Date (Date the DEF 14A was filed with the SEC.)
Key Players & Entities
- Travere Therapeutics, Inc. (company) — Filer
- Retrophin, Inc. (company) — Former Company Name
- Desert Gateway, Inc. (company) — Former Company Name
FAQ
What is the total compensation for the Principal Executive Officer (PEO) in 2024?
The filing provides details on equity awards granted and their fair value, but the total cash and stock compensation for the PEO is not explicitly stated in the provided snippet.
How many Non-PEO/Neo members received equity awards in 2024?
The filing indicates that equity awards were granted to 'NonPeoNeoMember' in 2024, but the exact number of individuals is not specified in the provided snippet.
What was the fair value of equity awards granted to PEOs in 2024?
The filing references 'EqtyAwrdsInSummryCompstnTblForAplblYrMember' and 'EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember' for PEOs in 2024, indicating fair value reporting, but the specific dollar amount is not in the snippet.
When did Travere Therapeutics change its name from Retrophin, Inc.?
Travere Therapeutics, Inc. changed its name from Retrophin, Inc. on February 20, 2013 (20130220).
What is the business address of Travere Therapeutics?
The business address for Travere Therapeutics, Inc. is 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA 92130.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 1, 2025 regarding Travere Therapeutics, Inc. (TVTX).